TABLE 4.
Status of lipid-lowering therapy at various time points during follow-up
| Follow-up at 12 months | Intervention group (n = 57) | Control group(n = 56) | P |
|---|---|---|---|
| Dose of lipid-lowering agent prescribed, % of maximal recommended dose (mean ± SD) | 46.5 ± 20.6 | 39.7 ± 26.3 | NS* |
| Number of patients without a lipid-lowering agent | 0 | 5 | <0.03† |
| Number of patients on a combination of lipid-lowering agents | 3 | 0 | NS† |
| Follow-up at 18 months | Intervention group (n = 56) | Control group (n = 55) | P |
| Dose of lipid-lowering agent prescribed, % of maximal recommended dose (mean ± SD) | 43.1 ± 23.0 | 37.0 ± 28.4 | NS* |
| Number of patients without a lipid-lowering agent | 0 | 5 | <0.03† |
| Number of patients on a combination of lipid-lowering agents | 3 | 0 | NS† |
See the ‘Patients and Methods’ section for details on calculating the percentage of maximal recommended dose;
*
Nonpaired Student’s t test;
†
Fisher’s exact test (as frequencies of several cells were less than five). NS Not significant